Scarica l'app Stockscreener
144.74
1.87%
-2.76
Dopo l'orario di chiusura:
144.85
0.11
+0.08%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$147.50
Aprire:
$147.65
Volume 24 ore:
4.79M
Relative Volume:
0.77
Capitalizzazione di mercato:
$179.47B
Reddito:
$29.79B
Utile/perdita netta:
$9.22B
Rapporto P/E:
19.69
EPS:
7.3494
Flusso di cassa netto:
$10.23B
1 W Prestazione:
-4.10%
1M Prestazione:
-3.26%
6M Prestazione:
+3.60%
1 anno Prestazione:
+30.92%
Intervallo 1D:
$144.00
$148.00
Intervallo di 1 settimana:
$144.00
$152.74
Portata 52W:
$109.66
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Nome
Gilead Sciences Inc
Settore
Industria
Telefono
(650) 574-3000
Indirizzo
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
144.74 | 187.15B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,142.85 | 1.02T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.03 | 653.61B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
262.82 | 467.12B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
144.30 | 367.07B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
141.00 | 276.48B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-10 | Iniziato | Jefferies | Buy |
| 2026-02-20 | Iniziato | Barclays | Equal Weight |
| 2026-02-11 | Reiterato | Needham | Buy |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-08-19 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Aggiornamento | Truist | Hold → Buy |
| 2025-07-25 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Reiterato | Oppenheimer | Outperform |
| 2025-02-18 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Aggiornamento | DZ Bank | Hold → Buy |
| 2025-01-10 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-11-08 | Downgrade | Maxim Group | Buy → Hold |
| 2024-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-07 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Reiterato | Maxim Group | Buy |
| 2024-04-24 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Downgrade | Truist | Buy → Hold |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-09-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-09-06 | Iniziato | HSBC Securities | Reduce |
| 2023-07-24 | Reiterato | Barclays | Equal Weight |
| 2023-05-16 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Ripresa | Piper Sandler | Overweight |
| 2023-01-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Ripresa | BofA Securities | Neutral |
| 2022-12-09 | Downgrade | DZ Bank | Buy → Hold |
| 2022-10-31 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Reiterato | BMO Capital Markets | Market Perform |
| 2022-10-28 | Reiterato | Cowen | Outperform |
| 2022-10-28 | Reiterato | JP Morgan | Overweight |
| 2022-10-28 | Reiterato | Jefferies | Buy |
| 2022-10-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-10-28 | Aggiornamento | Truist | Hold → Buy |
| 2022-10-28 | Reiterato | Wells Fargo | Equal Weight |
| 2022-10-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-28 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-02 | Reiterato | BofA Securities | Neutral |
| 2022-02-02 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-02-02 | Reiterato | Truist | Hold |
| 2022-02-02 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Argus | Hold → Buy |
| 2022-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Ripresa | Piper Sandler | Neutral |
| 2021-10-20 | Ripresa | Cowen | Outperform |
| 2021-07-30 | Reiterato | BMO Capital Markets | Market Perform |
| 2021-07-30 | Reiterato | RBC Capital Mkts | Outperform |
| 2021-04-01 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Aggiornamento | Redburn | Neutral → Buy |
| 2021-01-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-09-30 | Ripresa | Jefferies | Buy |
| 2020-09-15 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-07-31 | Reiterato | Credit Suisse | Neutral |
| 2020-07-31 | Reiterato | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Reiterato | Piper Sandler | Overweight |
| 2020-07-31 | Reiterato | RBC Capital Mkts | Outperform |
| 2020-07-31 | Reiterato | SunTrust | Hold |
| 2020-07-31 | Reiterato | Wells Fargo | Equal Weight |
| 2020-07-20 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Aggiornamento | SunTrust | Sell → Hold |
| 2020-05-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Downgrade | SunTrust | Hold → Sell |
| 2020-04-27 | Downgrade | UBS | Buy → Neutral |
| 2020-04-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Downgrade | CFRA | Hold → Sell |
Mostra tutto
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Confluence Investment Management LLC Cuts Position in Gilead Sciences, Inc. $GILD - MarketBeat
More Upside Awaits for Gilead Sciences Stock. Stay Invested. - Barron's
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Gilead expands lenacapavir licenses: Gilead Sciences stock has 6.53 percent upside - AD HOC NEWS
Gilead Sciences stock pre-market at EUR 131.75: plus 0.54 percent - AD HOC NEWS
Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors - Yahoo Finance
Gilead Sciences, Inc. (GILD) stock price, news, quote and history - uk.finance.yahoo.com
Gilead Sciences (NASDAQ:GILD) Stock: Stronger HIV Sales Meet Weaker Reported Earnings - kalkine.ca
Can Lenacapavir Power Gilead Sciences (GILD)’s Next Growth Phase? - Yahoo Finance
Gilead vs. Intuitive Surgical: Which Healthcare Stock Offers the Better Risk-Adjusted Upside? - Yahoo Finance
Gilead vs. Danaher: Which Healthcare Growth Story is More Convincing? - Yahoo Finance
Can Gilead Sciences (GILD) Justify Its Price As It Raises 2026 Guidance And Dividend? - Yahoo Finance
Gilead Sciences (GILD) Share Price, News, Stock Market Cap NASDAQ - TechGraph
CEUX:GISd Dividend: Does Gilead Sciences Inc Pay a Dividend? - GuruFocus
Gilead vs. Medtronic: Which Healthcare Stock Offers the Better Mix of Growth and Income? - Insider Monkey
Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward? - Yahoo Finance
Gilead or Johnson & Johnson: Is Faster Growth Better than Greater Diversification? - Yahoo Finance
Gilead’s HIV Concentration or Pfizer’s Patent Cliff: Which Risk is Easier to Own? - Insider Monkey
Form 4 Gilead Sciences Inc For: 26 September By Investing.com - Investing.com Nigeria
Gilead Sciences, Inc. (NASDAQ:GILD) Stock Has Average Price Target of $158.78 According to Analysts - MarketBeat
Gilead Sciences stock closes at USD 149.69, down 1.11 percent at the close - AD HOC NEWS
UBS Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $175 - Moomoo
Gilead Sciences stock falls 1.11 percent despite revenue growth - AD HOC NEWS
Gilead Sciences, Inc. $GILD Stake Decreased by Envestnet Asset Management Inc. - MarketBeat
Gilead Sciences stock heads into the open after a 0.4 percent gain - AD HOC NEWS
Gilead Sciences Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Form DEF 14A Gilead Sciences Inc For: 24 September By Investing.com - Investing.com Canada
Gilead Sciences stock slips 0.85 percent ahead of the open - AD HOC NEWS
Gilead: HIV Growth Is Not Enough At The Current Price (NASDAQ:GILD) - Seeking Alpha
Gilead Sciences stock slips 1.30 percent at the close - AD HOC NEWS
Gilead Sciences, Inc. (GILD) latest stock news and headlines - Yahoo Finance Singapore
Gilead Sciences stock slips as earnings estimates shift - AD HOC NEWS
Can Gilead Sciences (NASDAQ:GILD) turn HIV leadership and oncology development into a stronger market story? - Kalkine Media
Gilead Sciences, Inc. (GILD) Stock Price, News, Quote & History - Yahoo! Finance Canada
Gilead Sciences stock slips 0.7 percent ahead of the open - AD HOC NEWS
Gilead Sciences Research Scholars Program in Solid Tumors – US 2026 - Oncodaily
Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH - The Motley Fool
Gilead Sciences (GILD) Stock Moves 1.40%: What You Should Know - Yahoo Finance
Gilead Sciences stock slips 0.7 percent at the close - AD HOC NEWS
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Andra AP fonden Sells 11,400 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences FY2026 EPS Increased by Erste Group Bank - MarketBeat
THNR's Weight-Loss Index Swaps Hims & Hers for Gilead - ETF Database
Here's How Much $1000 Invested In Gilead Sciences 5 Years Ago Would Be Worth Today - Benzinga
Gilead Sciences stock holds near 52-week high as HIV prevention deal and analyst optimism support va - AD HOC NEWS
Gilead Sciences, Inc. (GILD) Stock Analysis: Exploring Revenue Growth and Strategic Collaborations - DirectorsTalk Interviews
Erste Group Bank Estimates Gilead Sciences FY2027 Earnings - MarketBeat
Gilead Sciences stock heads into the open after a 0.52% dip - ad-hoc-news.de
Gilead Sciences stock gains as HIV drug access expands - AD HOC NEWS
Why Morgan Stanley likes Gilead’s HIV prevention play - thestreet.com
Why Is Gilead Sciences (GILD) Widening Lenacapavir Access Across 120 Countries? - Yahoo Finance
Gilead Sciences Inc Azioni (GILD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Gilead Sciences Inc Azioni (GILD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Comm & Corp Aff Officer |
Sep 15 '26 |
Sale |
144.22 |
3,000 |
432,646 |
116,684 |
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):